2015 American Transplant Congress
Galectin-9 Protects Mouse Liver Transplants Against Ischemia-Reperfusion Injury
Dept of Surgery, Dumont-UCLA Liver Transplant Center, Los Angeles, CA.
Background:Although Galecin 9 (Gal-9) negatively regulates Th1-type alloimmunity by binding to T-cell Immunoglobulin Mucin-3 (TIM-3) on activated Th1 cells, its role in liver ischemia-reperfusion injury…2015 American Transplant Congress
A Tool to Estimate Probability of Outcomes on the Liver Transplant Waiting List
The probability of liver transplant (LTX) and death for candidates varies by donation service area (DSA), making it difficult for candidates to understand the likely…2015 American Transplant Congress
The Higher MFI of De Novo Donor-Specific Anti-HLA Antibodies Is Correlated With Graft Fibrosis Progression in Living Donor Liver Transplantation
Background. It has been shown that the development of de novo donor-specific anti-HLA antibodies (DSA) is associated with poorer graft outcome in kidney transplantation. However…2015 American Transplant Congress
Interferon-Free Sofosvir/Ribavirin Treatment Achieves Excellent Sustained Viral Response in Post Liver Transplant HCV Recipients
Purpose: HCV is the leading cause of end-stage liver disease, universally recurring in the post-transplant setting. Studies have shown disappointing results after first generation protease…2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Comparison of Risk Factors and Outcomes of Daptomycin-Susceptible and -Nonsusceptible Enterococcus Infections in Liver Transplant Recipients
University of Virginia, Charlottesville, VA.
PurposeDaptomycin (DAP) has become an important therapeutic agent to treat infections due to vancomycin-resistant Enterococcus faecium (VRE), including in liver transplant recipients (LTRs); however, DAP-nonsusceptible…2015 American Transplant Congress
Inside Out Autologous Neo-Liver Fabrication
Surgery, Stanford University School of Medicine, Stanford, CA.
Background: Creation of patient-specific replacement organs promises to address major shortcomings in transplantation. We previously described an approach to fabricate autologous, vascularized neo-organs by using…2015 American Transplant Congress
Consideration of the Futility of Transplant: 50% Mortality at 5 Years
Baylor University Medical Center, Dallas, TX.
Introduction: Transplant recipients are globally sicker at the time of liver transplantation (LT) in the current era. We sought to devise and validate a model…2015 American Transplant Congress
Vitamin D Deficiency in Liver Transplant Recipients: Prevalence, Risk Factors, and Outcomes
Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Vitamin D is known to be immunomodulatory, and its deficiency is associated with multiple chronic health problems in the general population. The objective of this…2015 American Transplant Congress
Listing for Liver Transplantation of Patients With Hepatocellular Carcinoma Using the Extended Toronto Criteria; an Intention-to-Treat Analysis
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
The role of liver transplantation for patients whose HCC exceeds Milan criteria remains controversial. At the University of Toronto, we have reported survivals of a…
- « Previous Page
- 1
- …
- 161
- 162
- 163
- 164
- 165
- …
- 180
- Next Page »